Can a smaller dose of this cancer drug still work? new trial aims to find out
NCT ID NCT07576725
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-cost dosing. The study will enroll 50 participants with cancers like melanoma, lung cancer, and kidney cancer that cannot be surgically removed or have spread.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab (a type of immunotherapy drug)
What this could lead to
If successful, this could show that a lower, less frequent dose of nivolumab works as well as the standard dose, making treatment more affordable and accessible worldwide.
What could go wrong
This is a small, early-phase trial (50 people) across many cancer types, so results may not apply to all. Lower dosing might be less effective or have different side effects than standard dosing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Uganda Cancer Institute
Kampala, 3935, Uganda
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact